Literature DB >> 20668920

Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.

Robert Ramer1, Anja Rohde, Jutta Merkord, Helga Rohde, Burkhard Hinz.   

Abstract

PURPOSE: Using human lung cancer cells, we evaluated the involvement of plasminogen activator inhibitor-1 (PAI-1) in the anti-invasive action of cannabidiol, a non-psychoactive cannabinoid.
METHODS: Invasion was quantified by a modified Boyden chamber assay. PAI-1 protein in cell culture media and PAI-1 mRNA were determined by immunoblotting and RT-PCR, respectively.
RESULTS: Cannabidiol caused a profound inhibition of A549 cell invasion, accompanied by a decreased expression and secretion of PAI-1. Cannabidiol's effects on PAI-1 secretion and invasion were suppressed by antagonists to CB(1) and CB(2) receptors as well as to transient receptor potential vanilloid 1. Recombinant human PAI-1 and PAI-1 siRNA led to a concentration-dependent up- and down-regulation of invasiveness, respectively, suggesting a crucial role of PAI-1 in A549 invasiveness. Evidence for a causal link between cannabidiol's effects on PAI-1 and invasion was provided by experiments showing a reversal of its anti-invasive action by addition of recombinant PAI-1 at non-proinvasive concentrations. Key data were confirmed in two other human lung cancer cell lines (H460, H358). In vivo, a significant downregulation of PAI-1 protein by cannabidiol was demonstrated in A549 xenografts.
CONCLUSION: Our data provide evidence for a hitherto unknown mechanism underlying the anti-invasive action of cannabidiol on human lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668920     DOI: 10.1007/s11095-010-0219-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  46 in total

1.  Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

Authors:  Alessia Ligresti; Aniello Schiano Moriello; Katarzyna Starowicz; Isabel Matias; Simona Pisanti; Luciano De Petrocellis; Chiara Laezza; Giuseppe Portella; Maurizio Bifulco; Vincenzo Di Marzo
Journal:  J Pharmacol Exp Ther       Date:  2006-05-25       Impact factor: 4.030

2.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

Authors:  L S Gutierrez; A Schulman; T Brito-Robinson; F Noria; V A Ploplis; F J Castellino
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

3.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors:  G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Glucocorticoid-regulated adipose tissue secretion of PAI-1, but not IL-6, TNFalpha or leptin in vivo.

Authors:  J Uddén; P Eriksson; J Hoffstedt
Journal:  Horm Metab Res       Date:  2002 Nov-Dec       Impact factor: 2.936

Review 5.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

6.  Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.

Authors:  Hannele Yki-Järvinen; Jussi Sutinen; Angela Silveira; Elena Korsheninnikova; Rachel M Fisher; Katja Kannisto; Ewa Ehrenborg; Per Eriksson; Anders Hamsten
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-20       Impact factor: 8.311

7.  Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.

Authors:  Barbara Costa; Gabriella Giagnoni; Chiara Franke; Anna Elisa Trovato; Mariapia Colleoni
Journal:  Br J Pharmacol       Date:  2004-08-16       Impact factor: 8.739

8.  5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.

Authors:  P Massi; M Valenti; A Vaccani; V Gasperi; G Perletti; E Marras; F Fezza; M Maccarrone; D Parolaro
Journal:  J Neurochem       Date:  2007-11-17       Impact factor: 5.372

Review 9.  The plasminogen activator inhibitor "paradox" in cancer.

Authors:  Bernd R Binder; Judit Mihaly
Journal:  Immunol Lett       Date:  2008-05-02       Impact factor: 3.685

10.  Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1.

Authors:  Robert Ramer; Jutta Merkord; Helga Rohde; Burkhard Hinz
Journal:  Biochem Pharmacol       Date:  2009-11-13       Impact factor: 5.858

View more
  26 in total

1.  Cannabidiol inhibits angiogenesis by multiple mechanisms.

Authors:  M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Cannabidiol as potential anticancer drug.

Authors:  Paola Massi; Marta Solinas; Valentina Cinquina; Daniela Parolaro
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review.

Authors:  Camren G Heider; Sasha A Itenberg; Jiajia Rao; Hang Ma; Xian Wu
Journal:  Biology (Basel)       Date:  2022-05-26

Review 4.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

5.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

6.  In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Authors:  T Fisher; H Golan; G Schiby; S PriChen; R Smoum; I Moshe; N Peshes-Yaloz; A Castiel; D Waldman; R Gallily; R Mechoulam; A Toren
Journal:  Curr Oncol       Date:  2016-03-16       Impact factor: 3.677

7.  Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium.

Authors:  Yehoshua Maor; Jinlong Yu; Paula M Kuzontkoski; Bruce J Dezube; Xuefeng Zhang; Jerome E Groopman
Journal:  Genes Cancer       Date:  2012-07

Review 8.  Anti-tumour actions of cannabinoids.

Authors:  Burkhard Hinz; Robert Ramer
Journal:  Br J Pharmacol       Date:  2018-08-07       Impact factor: 8.739

9.  Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis.

Authors:  Toshihiro Seike; Kyota Fujita; Yukiko Yamakawa; Mizuho A Kido; Soichi Takiguchi; Norihiro Teramoto; Haruo Iguchi; Mami Noda
Journal:  Clin Exp Metastasis       Date:  2010-10-17       Impact factor: 5.150

Review 10.  Cannabinoids as anticancer drugs: current status of preclinical research.

Authors:  Burkhard Hinz; Robert Ramer
Journal:  Br J Cancer       Date:  2022-03-11       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.